Journal of nuclear medicine : official publication, Society of Nuclear Medicine
-
Comparative Study Clinical Trial
Left ventricular ejection fraction and volumes from gated blood-pool SPECT: comparison with planar gated blood-pool imaging and assessment of repeatability in patients with heart failure.
Gated blood-pool SPECT (GBPS) has several potential advantages over planar radionuclide ventriculography (PRNV), including the possibility of greater repeatability of left ventricular ejection fraction (LVEF) and the noninvasive calculation of left ventricular end-systolic volume and left ventricular end-diastolic volume (LVEDV). The aim of this study was to assess the repeatability of LVEF and LVEDV from GBPS and to compare LVEF with those from PRNV. ⋯ GBPS provides a less repeatable measurement of LVEF than PRNV. Repeatability of LVEDV measurements from GBPS is poor.
-
Clinical Trial Controlled Clinical Trial
Statistical image analysis of cerebral blood flow in vascular dementia with small-vessel disease.
Small-vessel disease with dementia, which is the most frequent type of vascular dementia (VaD), often shows a cerebral blood flow (CBF) distribution with no obvious focal abnormalities and is therefore difficult to evaluate objectively. In this study, we combined CBF SPECT with 3-dimensional fractal analysis (3D-FA) to quantitatively assess the heterogeneity of CBF distribution and with 3-dimensional stereotactic surface projections (3D-SSP) to evaluate the distribution of CBF. We then evaluated the clinical validity of these techniques for the imaging diagnosis of VaD. ⋯ CBF SPECT images showed higher mean FD values in the VaD group than in the control group, suggesting a difference in the heterogeneity of CBF. Image processing with 3D-SSP successfully revealed that reduced cortical blood flow could be divided into 2 patterns. Because image analysis techniques, such as 3D-FA and 3D-SSP, allowed the simple and objective evaluation of CBF in patients with VaD, these methods seem to be useful for detailed examination of the blood flow pattern detected by CBF SPECT in patients with VaD.
-
This study is a retrospective analysis of 124 differentiated thyroid cancer patients who underwent dosimetric evaluation using MIRD methodology over a period of 15 y. The objectives of the study were to demonstrate the clinical use of dosimetry-guided radioactive iodine ([RAI] (131)I) treatment and the safe and effective application of a 3-Gy bone marrow (BM) dose in patients with differentiated thyroid cancer. ⋯ Dosimetry-guided RAI treatment allows administration of the maximum possible RAI dose to achieve the maximum therapeutic benefit. Estimation of tumor dose rates helps to determine the curative versus the palliative intent of the therapy.
-
In patients with gastroenteropancreatic (GEP) neuroendocrine tumors, we investigated the usefulness of somatostatin receptor scintigraphy (SRS) in the detection of liver metastasis, which represents the most important prognostic factor in these tumors, and in the management of affected patients. ⋯ (111)In-Pentetreotide SRS is a useful diagnostic tool in the detection of liver metastases in GEP tumor patients. In particular, SPECT proved to be significantly more sensitive and accurate than both planar imaging and CIP. Moreover, SPECT was also the most reliable procedure to obtain correct patient classification, thus guiding the most appropriate therapeutic strategy.
-
Ibritumomab tiuxetan is an anti-CD20 murine IgG1 kappa monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan, which securely chelates (111)In for imaging or dosimetry and (90)Y for radioimmunotherapy (RIT). Dosimetry and pharmacokinetic data from 4 clinical trials of (90)Y-ibritumomab tiuxetan RIT for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) were combined and assessed for correlations with toxicity data. ⋯ Relapsed or refractory NHL in patients with adequate bone marrow reserve and <25% bone marrow involvement by NHL can be treated safely with (90)Y-ibritumomab tiuxetan RIT on the basis of a fixed, weight-adjusted dosing schedule. Dosimetry and pharmacokinetic results do not correlate with toxicity.